Lupin has kicked off the new year with multiple US launches and approvals, chief among them its introduction of the first generic rival to Bausch + Lomb’s Prolensa (bromfenac) 0.07% ophthalmic solution, for which the Indian firm will enjoy 180-day first-to-file exclusivity.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?